Ero sivun ”Etanersepti” versioiden välillä
Siirry navigaatioon
Siirry hakuun
[katsottu versio] | [katsottu versio] |
Poistettu sisältö Lisätty sisältö
Ei muokkausyhteenvetoa |
Ei muokkausyhteenvetoa |
||
Rivi 1: | Rivi 1: | ||
'''Enbrel''' on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with [[tumor necrosis factor]] (TNF; a soluble inflammatory cytokine) by acting as a [[TNF inhibitor]]. Pfizer describes in a [[U.S. Securities and Exchange Commission|SEC]] filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.<ref>[http://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm Sales reached $3b in 2010]</ref> |
'''Enbrel''' on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with [[tumor necrosis factor]] (TNF; a soluble inflammatory cytokine) by acting as a [[TNF inhibitor]]. Pfizer describes in a [[U.S. Securities and Exchange Commission|SEC]] filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.<ref>[http://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm Sales reached $3b in 2010]</ref> |
||
==Licensed indications== |
|||
In the USA the FDA has licenced Enbrel for : |
|||
*Moderate to Severe [[Rheumatoid Arthritis]] (RA) (Nov 1998) |
|||
*Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) (1999) |
|||
*Psoriatic Arthritis (2002) |
|||
*[[Ankylosing Spondylitis]] (AS) (July 2003)<ref>http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01240.html FDA</ref> |
|||
*Moderate to Severe Plaque Psoriasis (April 2004) |
|||
===Viitteet=== |
===Viitteet=== |
Versio 15. syyskuuta 2012 kello 01.22
Enbrel on lääke joka hoitaa autoimmuunisairauksia TNF-infektoituneilla. is a drug that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. Pfizer describes in a SEC filing that the drug is used to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Sales reached record $3.3 billion in 2010.[1]
Licensed indications
In the USA the FDA has licenced Enbrel for :
- Moderate to Severe Rheumatoid Arthritis (RA) (Nov 1998)
- Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) (1999)
- Psoriatic Arthritis (2002)
- Ankylosing Spondylitis (AS) (July 2003)[2]
- Moderate to Severe Plaque Psoriasis (April 2004)